Adagene, Third Arc Bio expand SAFEbody masked CD3 T-cell engager collaboration with first lead pick
ADAG•Regional rights retained by Adagene
Adagene retained a no-cost option to develop and commercialize the candidates in Greater China, Singapore, South Korea.
Potential payments to Adagene increased
Total potential payments to Adagene increased, including development milestones and commercial milestones.
Collaboration expanded after first lead pick
Adagene broadened its strategic licensing collaboration with Third Arc Bio after Third Arc selected the first lead masked CD3 T cell engager.
Third Arc to fund clinical development under revised terms
Third Arc will sponsor and fund clinical development under revised terms that shift the deal toward an integrated asset and technology partnership.
